Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H24ClN3S.2C4H4O4 |
Molecular Weight | 606.087 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCN(CCCN2C3=CC(Cl)=CC=C3SC4=C2C=CC=C4)CC1
InChI
InChIKey=DSKIOWHQLUWFLG-SPIKMXEPSA-N
InChI=1S/C20H24ClN3S.2C4H4O4/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24;2*5-3(6)1-2-4(7)8/h2-3,5-8,15H,4,9-14H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C20H24ClN3S |
Molecular Weight | 373.943 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://apm.amegroups.com/article/view/1039/1266
Curator's Comment: Description was created based on several sources, including
http://apm.amegroups.com/article/view/1039/1266
Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. It also exhibits alpha-adrenergic blocking effect on α1 receptros and may depress the release of hypothalamic and hypophyseal hormones. Prochlorperazine is used for the control of severe nausea and vomiting, for the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety.
Prochlorperazine may be an effective treatment of acute headaches and refractory chronic daily headache.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23954492 |
|||
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16860311 |
22.6 µM [IC50] | ||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COMPAZINE Approved UseTo control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Launch Date1959 |
|||
Primary | COMPAZINE Approved UseTo control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Launch Date1959 |
|||
Primary | COMPAZINE Approved UseTo control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Launch Date1959 |
|||
Primary | COMPAZINE Approved UseTo control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Launch Date1959 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9 ng/mL |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.3 ng × h/mL |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.1 h |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9 h |
12.5 mg/kg single, intravenous dose: 12.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROCHLORPERAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
180 mg/m2 1 times / day multiple, intravenous MTD Dose: 180 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 180 mg/m2, 1 times / day Sources: |
unhealthy, 38-77 |
DLT: Sedation, Hypotension... Disc. AE: Akathisia... Dose limiting toxicities: Sedation (grade 3, 25%) AEs leading toHypotension (grade 3, 25%) discontinuation/dose reduction: Akathisia (50%) Sources: |
1.2 mg/kg 1 times / day multiple, intravenous MTD Dose: 1.2 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 1.2 mg/kg, 1 times / day Sources: |
unhealthy |
DLT: Hypotension, Restlessness... Dose limiting toxicities: Hypotension (33.3%) Sources: Restlessness (100%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Akathisia | 50% Disc. AE |
180 mg/m2 1 times / day multiple, intravenous MTD Dose: 180 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 180 mg/m2, 1 times / day Sources: |
unhealthy, 38-77 |
Hypotension | grade 3, 25% DLT |
180 mg/m2 1 times / day multiple, intravenous MTD Dose: 180 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 180 mg/m2, 1 times / day Sources: |
unhealthy, 38-77 |
Sedation | grade 3, 25% DLT |
180 mg/m2 1 times / day multiple, intravenous MTD Dose: 180 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 180 mg/m2, 1 times / day Sources: |
unhealthy, 38-77 |
Restlessness | 100% DLT |
1.2 mg/kg 1 times / day multiple, intravenous MTD Dose: 1.2 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 1.2 mg/kg, 1 times / day Sources: |
unhealthy |
Hypotension | 33.3% DLT |
1.2 mg/kg 1 times / day multiple, intravenous MTD Dose: 1.2 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 1.2 mg/kg, 1 times / day Sources: |
unhealthy |
PubMed
Title | Date | PubMed |
---|---|---|
Emergency! Prochlorperazine-induced dystonia. | 1999 Nov |
|
Prochlorperazine-induced extrapyramidal effects mimicking meningitis in a child. | 2000 Jun |
|
Photosensitivity associated with fluorouracil, prochlorperazine, and topical tretinoin. | 2001 Feb |
|
Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. | 2001 Feb |
|
[Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals]. | 2001 Jan-Mar |
|
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. | 2002 |
|
Myeloperoxidase-generated phenothiazine cation radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase. | 2002 Apr-Jun |
|
Upper airway obstruction resulting from an antiemetic. | 2002 Dec |
|
Medical management of Meniere's disease. | 2002 Jun |
|
Akathisia: problematic but preventable. | 2002 May |
|
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. | 2003 Dec |
|
An evaluation of protein assays for quantitative determination of drugs. | 2003 Jul 31 |
|
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. | 2004 Feb |
|
Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. | 2004 Jun 29 |
|
Postmortem distribution of the novel antipsychotic drug quetiapine. | 2004 May-Jun |
|
The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. | 2005 Jan |
|
Prevention and treatment of postoperative nausea and vomiting. | 2005 Jun 15 |
|
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. | 2005 Nov-Dec |
Patents
Sample Use Guides
DOSAGE AND ADMINISTRATION–ADULTS
1. To Control Severe Nausea and Vomiting: Adjust dosage to the response of the individual. Begin with the lowest recommended dosage.
Oral Dosage–Tablets: Usually one 5 mg or 10 mg tablet 3 or 4 times daily. Daily dosages above 40 mg should be used only in resistant cases.
Spansule capsules: Initially, usually one 15 mg capsule on arising or one 10 mg capsule q12h. Daily doses above 40 mg should be used only in resistant cases.
11
Rectal Dosage: 25 mg twice daily.
I.M. Dosage: Initially 5 to 10 mg (1 to 2 mL) injected deeply into the upper outer quadrant of the buttock. If necessary, repeat every 3 or 4 hours. Total I.M. dosage should not exceed 40 mg per day.
I.V. Dosage: 2½ to 10 mg (½ to 2 mL) by slow I.V. injection or infusion at a rate not to exceed 5 mg per minute. Compazine Injection may be administered either undiluted or diluted in isotonic solution. A single dose of the drug should not exceed 10 mg; total I.V. dosage should not exceed 40 mg per day. When administered I.V., do not use bolus injection. Hypotension is a possibility if the drug is given by I.V. injection or infusion.
2. Adult Surgery (for severe nausea and vomiting): Total parenteral dosage should not exceed 40 mg per day. Hypotension is a possibility if the drug is given by I.V. injection or infusion.
I.M. Dosage: 5 to 10 mg (1 to 2 mL) 1 to 2 hours before induction of anesthesia (repeat once in 30 minutes, if necessary), or to control acute symptoms during and after surgery (repeat once if necessary).
I.V. Dosage: 5 to 10 mg (1 to 2 mL) as a slow I.V. injection or infusion 15 to 30 minutes before induction of anesthesia, or to control acute symptoms during or after surgery. Repeat once if necessary. Compazine (prochlorperazine) may be administered either undiluted or diluted in isotonic solution, but a single dose of the drug should not exceed 10 mg. The rate of administration should not exceed 5 mg per minute. When administered I.V., do not use bolus injection.
3. In Adult Psychiatric Disorders: Adjust dosage to the response of the individual and according to the severity of the condition. Begin with the lowest recommended dose. Although response ordinarily is seen within a day or 2, longer treatment is usually required before maximal improvement is seen.
Oral Dosage:
Non-Psychotic Anxiety–Usual dosage is 5 mg 3 or 4 times daily; by Spansule capsule, usually one 15 mg capsule on arising or one 10 mg capsule q12h. Do not administer in doses of more than 20 mg per day or for longer than 12 weeks.
Psychotic Disorders including Schizophrenia–In relatively mild conditions, as seen in private psychiatric practice or in outpatient clinics, dosage is 5 or 10 mg 3 or 4 times daily.
In moderate to severe conditions, for hospitalized or adequately supervised patients, usual starting dosage is 10 mg 3 or 4 times daily. Increase dosage gradually until symptoms are controlled or side effects become bothersome. When dosage is increased by small increments every 2 or 3 days, side effects either do not occur or are easily controlled. Some patients respond satisfactorily on 50 to 75 mg daily. In more severe disturbances, optimum dosage is usually 100 to 150 mg daily.
I.M. Dosage: For immediate control of adult schizophrenic patients with severe symptomatology, inject an initial dose of 10 to 20 mg (2 to 4 mL) deeply into the upper outer quadrant of the buttock. Many patients respond shortly after the first injection. If necessary, however, repeat the initial dose every 2 to 4 hours (or, in resistant cases, every hour) to gain control of the patient. More than three or four doses are seldom necessary. After control is achieved, switch patient to an oral form of the drug at the same dosage level or higher. If, in rare cases, parenteral therapy is needed for a prolonged period, give 10 to 20 mg (2 to 4 mL) every 4
to 6 hours. Pain and irritation at the site of injection have seldom occurred. Subcutaneous administration is not advisable because of local irritation.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2833274
We have studied the effects of prochlorperazine on the activities of UDP-glucuronosyltransferase and glucose-6-phosphatase (glucose-6-P'ase) in rat liver microsomes. The activity of UDP-glucuronosyltransferase was increased in a graded fashion by addition of prochlorperazine. Maximal stimulation occurred at 1 mg prochlorperazine to 2 mg microsomal protein, which resulted in a 6-fold increase in activity.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:02 GMT 2025
by
admin
on
Mon Mar 31 17:45:02 GMT 2025
|
Record UNII |
I1T8O1JTL6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C740
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5281032
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
m9149
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
201-511-3
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
84-02-6
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
100000085101
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
1566001
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
DBSALT000998
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
Prochlorperazine maleate
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
I1T8O1JTL6
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
8436
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL728
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
I1T8O1JTL6
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
8706
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB04052MIG
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
DTXSID1049015
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY | |||
|
C775
Created by
admin on Mon Mar 31 17:45:02 GMT 2025 , Edited by admin on Mon Mar 31 17:45:02 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |